Using qRT-PCR, we validated 27 of the DEGs in SK-N-BE(2)-C cells and in two other Wnt3a/Rspo2 responsive neuroblastoma cell lines with different driver mutations, SK-N-AS (NRAS mutant) and SH-SY5Y cells (ALK mutant) following 6 hours and 24 hours of Wnt3a/Rspo2 treatment. The gene discussed is RSPO2; the disease is neuroblastoma.